Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10002526 | 1.00 | LTA4H (0.38) | LTA4HHRH2HRH1HRH3GNAI3 | |
| SCHEMBL11971816 | 0.89 | ADORA2A (0.37) | LTA4HADORA2APAX8 | |
| SCHEMBL11972135 | 0.89 | ADORA2A (0.37) | LTA4HADORA2APAX8 | |
| SCHEMBL27438407 | 0.89 | GNAI3 (0.41) | LTA4HHRH2HRH1HRH3GNAI3 | |
| SCHEMBL4103985 | 0.88 | GNAI3 (0.46) | HRH2HRH1HRH3GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL3430116 | 0.86 | GNAO1 (0.48) | HRH2HRH1HRH3GNAI3GNAO1 | |
| SCHEMBL1516424 | 0.83 | — | — | |
| SCHEMBL12927139 | 0.80 | GNAI3 (0.39) | LTA4HHRH2HRH1HRH3GNAI3 | |
| SCHEMBL20992134 | 0.79 | KDM1A (0.33) | LTA4HHRH2HRH1HRH3GNAI3 | |
| SCHEMBL22789404 | 0.79 | KDM1A (0.33) | LTA4HHRH2HRH1HRH3GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | disclosed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| CN-102596913-B | Cannabinoid receptor modulators | 艾尼纳制药公司 | 2016-11-09 | — | — | CN | disclosed |
| US-8778950-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | LTA4H 1320/4885HRH2 148/4885HRH1 108/4885 |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | LTA4H 478/4885HRH2 259/4885HRH1 1110/4885 |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | LTA4H 1320/4885HRH2 148/4885HRH1 108/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | LTA4H 1320/4885HRH2 148/4885HRH1 108/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | LTA4H 1320/4885HRH2 148/4885HRH1 108/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | LTA4H 478/4885HRH2 259/4885HRH1 1110/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | LTA4H 1320/4885HRH2 148/4885HRH1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.